Nektar TherapeuticsNKTRNASDAQ
Loading
Cash Flow PerformanceFair Value
Percentile Rank21
Studio
Year-over-Year Change

Free cash flow yield

Latest
-29.26%
↑ 28% vs avg
Percentile
P21
Within normal range
Streak
2 yr
Consecutive growthFair Value
Average
-40.87%
Historical baseline
PeriodValueYoY Change
2025-29.26%+68.4%
2024-92.63%+48.6%
2023-180.12%-146.0%
2022-73.22%-324.0%
2021-17.27%-63.6%
2020-10.56%-12.4%
2019-9.40%-179.0%
201811.89%+1329.2%
2017-0.97%+86.6%
2016-7.21%-